# 美國總統川普宣布與藥廠Regeneron達成協議，降低Medicaid受益人的藥品費用。

*biotech, business · news · 2026-04-23 · Devdiscourse*

## Key points

- 川普總統宣布與Regeneron達成價格協議，以降低Medicaid藥品費用。
- Regeneron的降膽固醇藥物Praluent將在TrumpRx平台以225美元售出。
- 該協議是「最惠國待遇」協議的一部分，旨在使美國藥價與國際接軌。
- Regeneron承諾增加在美國的研發投資，作為協議的一部分。
- Regeneron的新基因療法在持續的藥價辯論中獲得FDA批准。

In a significant move on Thursday, President Donald Trump revealed a groundbreaking agreement with drugmaker Regeneron aimed at lowering pharmaceutical costs for Medicaid recipients. This aligns with the White House's broader initiative to address high drug prices ahead of the midterm elections, reflecting Trump's ongoing efforts to achieve economic relief, particularly in healthcare. Under the deal, Regeneron will reduce prices for its existing and future drugs, including the cholesterol medication Praluent, which will be available for USD 225 on the discounted platform TrumpRx. This agreement, part of several 'most-favored-nation' deals, aims to bring U.S. drug prices in line with those of other developed countries. The President, with a history of lauding Regeneron, emphasized the potential electoral impact of such deals and mentioned Regeneron's commitment to substantial research and development investments in the U.S. Additionally, Regeneron's new gene therapy was approved by the FDA, underscoring the ongoing debate over drug-pricing strategies during Trump's administration.

**Companies:** Regeneron
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3885172-trump-strikes-deal-with-regeneron-for-discounted-drug-prices)

---

Canonical: https://newsio.io/zh-TW/n/b20c367e-3a65-426f-81a0-b8e67c421202/regeneronmedicaid
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works